Skip to main content
Erschienen in: Indian Journal of Hematology and Blood Transfusion 3/2018

03.03.2018 | Images

Acral Hyperpigmentation Resulting from Hydroxyurea Therapy in Primary Myelofibrosis

verfasst von: Apichat Kaewdech, Kumpol Aiempanakit, Benjawan Apinantriyo

Erschienen in: Indian Journal of Hematology and Blood Transfusion | Ausgabe 3/2018

Einloggen, um Zugang zu erhalten

Excerpt

A 77-year-old Asian man with congenital lymphedema had been diagnosed with JAK2-V617F mutation positive primary myelofibrosis for 2 years. After diagnosis, he was treated with hydroxyurea 500 mg/day. The patient has developed palmoplantar hyperpigmentation after receiving 22 months of hydroxyurea therapy (Fig. 1).
Literatur
2.
Zurück zum Zitat Kumar B, Saraswat A, Kaur I (2002) Mucocutaneous adverse effects of hydroxyurea: a prospective study of 30 psoriasis patients. Clin Exp Dermatol 27:8–13CrossRefPubMed Kumar B, Saraswat A, Kaur I (2002) Mucocutaneous adverse effects of hydroxyurea: a prospective study of 30 psoriasis patients. Clin Exp Dermatol 27:8–13CrossRefPubMed
Metadaten
Titel
Acral Hyperpigmentation Resulting from Hydroxyurea Therapy in Primary Myelofibrosis
verfasst von
Apichat Kaewdech
Kumpol Aiempanakit
Benjawan Apinantriyo
Publikationsdatum
03.03.2018
Verlag
Springer India
Erschienen in
Indian Journal of Hematology and Blood Transfusion / Ausgabe 3/2018
Print ISSN: 0971-4502
Elektronische ISSN: 0974-0449
DOI
https://doi.org/10.1007/s12288-018-0940-2

Weitere Artikel der Ausgabe 3/2018

Indian Journal of Hematology and Blood Transfusion 3/2018 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.